Valneva SE (NASDAQ: VALN) Stock Competitors & Peer Comparison
See VALN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for VALN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VALN | $6.76 | -0.88% | 660M | -3.30 | -$2.11 | N/A |
| VRTX | $548.44 | +1.51% | 139.1B | 28.80 | $19.03 | N/A |
| REGN | $824.80 | -0.22% | 85.9B | 18.28 | $45.63 | +0.44% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,002.97 | -3.39% | 64.7B | 93.84 | $11.08 | N/A |
| MRNA | $137.49 | +3.13% | 57.6B | -17.81 | -$8.15 | N/A |
| RVMDW | $11.95 | -2.61% | 46.3B | -1.64 | -$7.21 | N/A |
| RVMD | $208.66 | -1.45% | 44.5B | -23.75 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $370.48 | +0.36% | 40B | 65.93 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
VALN vs VRTX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, VRTX has a market cap of 139.1B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while VRTX trades at $548.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas VRTX's P/E ratio is 28.80. In terms of profitability, VALN's ROE is -1.53%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, VALN is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for VALN.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
VALN vs REGN Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, REGN has a market cap of 85.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while REGN trades at $824.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas REGN's P/E ratio is 18.28. In terms of profitability, VALN's ROE is -1.53%, compared to REGN's ROE of +0.14%. Regarding short-term risk, VALN is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for VALN.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
VALN vs VRNA Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VALN's ROE is -1.53%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, VALN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for VALN.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
VALN vs ARGX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ARGX has a market cap of 64.7B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ARGX trades at $1,002.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ARGX's P/E ratio is 93.84. In terms of profitability, VALN's ROE is -1.53%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, VALN is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
VALN vs MRNA Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, MRNA has a market cap of 57.6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while MRNA trades at $137.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas MRNA's P/E ratio is -17.81. In terms of profitability, VALN's ROE is -1.53%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, VALN is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for VALN.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
VALN vs RVMDW Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, RVMDW has a market cap of 46.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while RVMDW trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas RVMDW's P/E ratio is -1.64. In terms of profitability, VALN's ROE is -1.53%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, VALN is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for VALN.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
VALN vs RVMD Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, RVMD has a market cap of 44.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while RVMD trades at $208.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas RVMD's P/E ratio is -23.75. In terms of profitability, VALN's ROE is -1.53%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, VALN is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for VALN.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
VALN vs SGEN Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VALN's ROE is -1.53%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VALN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for VALN.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
VALN vs ONC Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ONC has a market cap of 40B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ONC trades at $370.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ONC's P/E ratio is 65.93. In terms of profitability, VALN's ROE is -1.53%, compared to ONC's ROE of +0.14%. Regarding short-term risk, VALN is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
VALN vs ALNY Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ALNY has a market cap of 31.6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ALNY trades at $233.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ALNY's P/E ratio is 42.56. In terms of profitability, VALN's ROE is -1.53%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, VALN is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
VALN vs BNTX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, BNTX has a market cap of 29.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while BNTX trades at $111.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas BNTX's P/E ratio is -15.12. In terms of profitability, VALN's ROE is -1.53%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, VALN is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
VALN vs INSM Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, INSM has a market cap of 27.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while INSM trades at $124.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas INSM's P/E ratio is -30.60. In terms of profitability, VALN's ROE is -1.53%, compared to INSM's ROE of -1.11%. Regarding short-term risk, VALN is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for VALN.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
VALN vs ROIV Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ROIV has a market cap of 26.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ROIV trades at $36.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ROIV's P/E ratio is -34.53. In terms of profitability, VALN's ROE is -1.53%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, VALN is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
VALN vs INCY Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, INCY has a market cap of 25.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while INCY trades at $127.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas INCY's P/E ratio is 17.18. In terms of profitability, VALN's ROE is -1.53%, compared to INCY's ROE of +0.30%. Regarding short-term risk, VALN is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for VALN.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
VALN vs UTHR Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, UTHR has a market cap of 21.8B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while UTHR trades at $511.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas UTHR's P/E ratio is 18.36. In terms of profitability, VALN's ROE is -1.53%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, VALN is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for VALN.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
VALN vs GMAB Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, GMAB has a market cap of 20.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while GMAB trades at $33.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas GMAB's P/E ratio is 25.21. In terms of profitability, VALN's ROE is -1.53%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, VALN is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for VALN.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
VALN vs BGNE Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VALN's ROE is -1.53%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, VALN is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for VALN.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
VALN vs DNA-WT Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VALN's ROE is -1.53%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, VALN is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for VALN.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
VALN vs JAZZ Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while JAZZ trades at $251.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas JAZZ's P/E ratio is 9.48. In terms of profitability, VALN's ROE is -1.53%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, VALN is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for VALN.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
VALN vs BBIO Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, BBIO has a market cap of 16B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while BBIO trades at $80.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas BBIO's P/E ratio is -21.79. In terms of profitability, VALN's ROE is -1.53%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, VALN is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for VALN.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
VALN vs ASND Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ASND trades at $250.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ASND's P/E ratio is -104.67. In terms of profitability, VALN's ROE is -1.53%, compared to ASND's ROE of +1.90%. Regarding short-term risk, VALN is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
VALN vs NBIX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, NBIX has a market cap of 15.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while NBIX trades at $152.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas NBIX's P/E ratio is 22.05. In terms of profitability, VALN's ROE is -1.53%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, VALN is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
VALN vs EXEL Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, EXEL has a market cap of 13.6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while EXEL trades at $54.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas EXEL's P/E ratio is 15.45. In terms of profitability, VALN's ROE is -1.53%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, VALN is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for VALN.Check EXEL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
VALN vs BMRN Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, BMRN has a market cap of 12.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while BMRN trades at $65.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas BMRN's P/E ratio is 32.07. In terms of profitability, VALN's ROE is -1.53%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, VALN is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for VALN.Check BMRN's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
VALN vs HALO Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, HALO has a market cap of 12.8B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while HALO trades at $107.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas HALO's P/E ratio is 20.18. In terms of profitability, VALN's ROE is -1.53%, compared to HALO's ROE of +1.81%. Regarding short-term risk, VALN is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for VALN.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
VALN vs KRTX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VALN's ROE is -1.53%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VALN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for VALN.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
VALN vs ARWR Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ARWR has a market cap of 12.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ARWR trades at $86.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ARWR's P/E ratio is -38.72. In terms of profitability, VALN's ROE is -1.53%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, VALN is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
VALN vs MDGL Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while MDGL trades at $510.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas MDGL's P/E ratio is -40.37. In terms of profitability, VALN's ROE is -1.53%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, VALN is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for VALN.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
VALN vs TECH Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while TECH trades at $72.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas TECH's P/E ratio is 37.28. In terms of profitability, VALN's ROE is -1.53%, compared to TECH's ROE of +0.09%. Regarding short-term risk, VALN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for VALN.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
VALN vs RNAM Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VALN's ROE is -1.53%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VALN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for VALN.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
VALN vs AXSM Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while AXSM trades at $206.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas AXSM's P/E ratio is -54.25. In terms of profitability, VALN's ROE is -1.53%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, VALN is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for VALN.Check AXSM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
VALN vs SMMT Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, SMMT has a market cap of 10.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while SMMT trades at $12.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas SMMT's P/E ratio is -11.75. In terms of profitability, VALN's ROE is -1.53%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, VALN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for VALN.Check SMMT's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
VALN vs PRAX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, PRAX has a market cap of 10.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while PRAX trades at $366.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas PRAX's P/E ratio is -29.08. In terms of profitability, VALN's ROE is -1.53%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, VALN is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check PRAX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
VALN vs KRYS Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while KRYS trades at $341.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas KRYS's P/E ratio is 43.43. In terms of profitability, VALN's ROE is -1.53%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VALN is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for VALN.Check KRYS's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
VALN vs PTGX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, PTGX has a market cap of 9.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while PTGX trades at $152.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas PTGX's P/E ratio is 149.90. In terms of profitability, VALN's ROE is -1.53%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, VALN is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check PTGX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
VALN vs IONS Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, IONS has a market cap of 9.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while IONS trades at $61.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas IONS's P/E ratio is -34.73. In terms of profitability, VALN's ROE is -1.53%, compared to IONS's ROE of -1.11%. Regarding short-term risk, VALN is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for VALN.Check IONS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
VALN vs KYMR Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, KYMR has a market cap of 9.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while KYMR trades at $118.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas KYMR's P/E ratio is -37.44. In terms of profitability, VALN's ROE is -1.53%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, VALN is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for VALN.Check KYMR's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
VALN vs CYTK Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while CYTK trades at $76.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas CYTK's P/E ratio is -10.64. In terms of profitability, VALN's ROE is -1.53%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, VALN is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for VALN.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
VALN vs RXDX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VALN's ROE is -1.53%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VALN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for VALN.Check RXDX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
VALN vs SYRE Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, SYRE has a market cap of 9.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while SYRE trades at $106.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas SYRE's P/E ratio is -54.61. In terms of profitability, VALN's ROE is -1.53%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, VALN is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for VALN.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
VALN vs IMVT Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, IMVT has a market cap of 9.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while IMVT trades at $43.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas IMVT's P/E ratio is -15.73. In terms of profitability, VALN's ROE is -1.53%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, VALN is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for VALN.Check IMVT's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
VALN vs NUVL Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas NUVL's P/E ratio is -21.79. In terms of profitability, VALN's ROE is -1.53%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VALN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for VALN.Check NUVL's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
VALN vs PCVX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, PCVX has a market cap of 9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while PCVX trades at $61.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas PCVX's P/E ratio is -8.21. In terms of profitability, VALN's ROE is -1.53%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, VALN is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check PCVX's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
VALN vs CRNX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while CRNX trades at $84.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas CRNX's P/E ratio is -16.80. In terms of profitability, VALN's ROE is -1.53%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VALN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for VALN.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
VALN vs IMGN Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VALN's ROE is -1.53%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VALN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for VALN.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
VALN vs ABVX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ABVX has a market cap of 8.4B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ABVX trades at $114.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ABVX's P/E ratio is -60.25. In terms of profitability, VALN's ROE is -1.53%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, VALN is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
VALN vs BPMC Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VALN's ROE is -1.53%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, VALN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for VALN.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
VALN vs APGE Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while APGE trades at $134.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas APGE's P/E ratio is -31.12. In terms of profitability, VALN's ROE is -1.53%, compared to APGE's ROE of -0.30%. Regarding short-term risk, VALN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for VALN.Check APGE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
VALN vs TGTX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while TGTX trades at $53.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas TGTX's P/E ratio is 19.66. In terms of profitability, VALN's ROE is -1.53%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, VALN is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
VALN vs CERE Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas CERE's P/E ratio is -16.47. In terms of profitability, VALN's ROE is -1.53%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VALN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for VALN.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
VALN vs IBRX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, IBRX has a market cap of 8.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while IBRX trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas IBRX's P/E ratio is -8.03. In terms of profitability, VALN's ROE is -1.53%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, VALN is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check IBRX's competition here
Alkermes plc (NASDAQ: ALKS)
VALN vs ALKS Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ALKS has a market cap of 8.1B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ALKS trades at $48.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ALKS's P/E ratio is 50.87. In terms of profitability, VALN's ROE is -1.53%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, VALN is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for VALN.Check ALKS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
VALN vs RYTM Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while RYTM trades at $111.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas RYTM's P/E ratio is -35.35. In terms of profitability, VALN's ROE is -1.53%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, VALN is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for VALN.Check RYTM's competition here
Metsera, Inc. (NASDAQ: MTSR)
VALN vs MTSR Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VALN's ROE is -1.53%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, VALN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for VALN.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
VALN vs CAI Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while CAI trades at $26.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas CAI's P/E ratio is 69.06. In terms of profitability, VALN's ROE is -1.53%, compared to CAI's ROE of +0.19%. Regarding short-term risk, VALN is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for VALN.Check CAI's competition here
CG Oncology Inc. (NASDAQ: CGON)
VALN vs CGON Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, CGON has a market cap of 6.8B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while CGON trades at $79.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas CGON's P/E ratio is -28.85. In terms of profitability, VALN's ROE is -1.53%, compared to CGON's ROE of -0.25%. Regarding short-term risk, VALN is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for VALN.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
VALN vs MRUS Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VALN's ROE is -1.53%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, VALN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for VALN.Check MRUS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
VALN vs SRRK Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, SRRK has a market cap of 6.8B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while SRRK trades at $57.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas SRRK's P/E ratio is -16.38. In terms of profitability, VALN's ROE is -1.53%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, VALN is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for VALN.Check SRRK's competition here
Arcellx, Inc. (NASDAQ: ACLX)
VALN vs ACLX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VALN's ROE is -1.53%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VALN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for VALN.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
VALN vs RETA Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas RETA's P/E ratio is -66.29. In terms of profitability, VALN's ROE is -1.53%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VALN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for VALN.Check RETA's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
VALN vs ORKA Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ORKA has a market cap of 6.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ORKA trades at $102.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ORKA's P/E ratio is -55.65. In terms of profitability, VALN's ROE is -1.53%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, VALN is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ORKA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
VALN vs BLTE Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while BLTE trades at $159.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas BLTE's P/E ratio is -86.13. In terms of profitability, VALN's ROE is -1.53%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, VALN is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for VALN.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
VALN vs CNTA Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas CNTA's P/E ratio is -22.63. In terms of profitability, VALN's ROE is -1.53%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VALN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for VALN.Check CNTA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
VALN vs DNTH Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, DNTH has a market cap of 6.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while DNTH trades at $110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas DNTH's P/E ratio is -26.77. In terms of profitability, VALN's ROE is -1.53%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, VALN is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for VALN.Check DNTH's competition here
Erasca, Inc. (NASDAQ: ERAS)
VALN vs ERAS Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ERAS has a market cap of 6.1B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ERAS trades at $17.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ERAS's P/E ratio is -18.96. In terms of profitability, VALN's ROE is -1.53%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, VALN is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ERAS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
VALN vs TVTX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while TVTX trades at $64.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas TVTX's P/E ratio is -146.02. In terms of profitability, VALN's ROE is -1.53%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, VALN is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check TVTX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
VALN vs COGT Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, COGT has a market cap of 6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while COGT trades at $36.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas COGT's P/E ratio is -16.73. In terms of profitability, VALN's ROE is -1.53%, compared to COGT's ROE of -0.73%. Regarding short-term risk, VALN is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for VALN.Check COGT's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
VALN vs DFTX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, DFTX has a market cap of 6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while DFTX trades at $43.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas DFTX's P/E ratio is N/A. In terms of profitability, VALN's ROE is -1.53%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, VALN is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check DFTX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
VALN vs XENE Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, XENE has a market cap of 5.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while XENE trades at $60.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas XENE's P/E ratio is -12.93. In terms of profitability, VALN's ROE is -1.53%, compared to XENE's ROE of -0.44%. Regarding short-term risk, VALN is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for VALN.Check XENE's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
VALN vs MIRM Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while MIRM trades at $96.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas MIRM's P/E ratio is -6.62. In terms of profitability, VALN's ROE is -1.53%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, VALN is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for VALN.Check MIRM's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
VALN vs PTCT Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while PTCT trades at $69.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas PTCT's P/E ratio is -29.97. In terms of profitability, VALN's ROE is -1.53%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, VALN is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for VALN.Check PTCT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
VALN vs LGND Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while LGND trades at $283.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas LGND's P/E ratio is 31.43. In terms of profitability, VALN's ROE is -1.53%, compared to LGND's ROE of +0.20%. Regarding short-term risk, VALN is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for VALN.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
VALN vs CDTX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VALN's ROE is -1.53%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, VALN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for VALN.Check CDTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
VALN vs CRSP Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while CRSP trades at $56.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas CRSP's P/E ratio is -12.21. In terms of profitability, VALN's ROE is -1.53%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, VALN is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for VALN.Check CRSP's competition here
Abcam plc (NASDAQ: ABCM)
VALN vs ABCM Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VALN's ROE is -1.53%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VALN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for VALN.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
VALN vs ISEE Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VALN's ROE is -1.53%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VALN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for VALN.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
VALN vs APLS Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas APLS's P/E ratio is 38.35. In terms of profitability, VALN's ROE is -1.53%, compared to APLS's ROE of +0.40%. Regarding short-term risk, VALN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for VALN.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
VALN vs ACAD Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ACAD has a market cap of 5.1B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ACAD trades at $29.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ACAD's P/E ratio is 13.29. In terms of profitability, VALN's ROE is -1.53%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, VALN is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
VALN vs DYN Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while DYN trades at $25.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas DYN's P/E ratio is -8.11. In terms of profitability, VALN's ROE is -1.53%, compared to DYN's ROE of -0.64%. Regarding short-term risk, VALN is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for VALN.Check DYN's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
VALN vs TERN Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas TERN's P/E ratio is -51.41. In terms of profitability, VALN's ROE is -1.53%, compared to TERN's ROE of -0.20%. Regarding short-term risk, VALN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for VALN.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
VALN vs EWTX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while EWTX trades at $44.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas EWTX's P/E ratio is -23.88. In terms of profitability, VALN's ROE is -1.53%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, VALN is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
VALN vs PBLS Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while PBLS trades at $38.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas PBLS's P/E ratio is -44.73. In terms of profitability, VALN's ROE is -1.53%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, VALN is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for VALN.Check PBLS's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
VALN vs FOLD Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VALN's ROE is -1.53%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VALN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for VALN.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
VALN vs AKRO Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VALN's ROE is -1.53%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, VALN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for VALN.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
VALN vs ALPN Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VALN's ROE is -1.53%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VALN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for VALN.Check ALPN's competition here
Celcuity Inc. (NASDAQ: CELC)
VALN vs CELC Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while CELC trades at $92.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas CELC's P/E ratio is -21.06. In terms of profitability, VALN's ROE is -1.53%, compared to CELC's ROE of -3.51%. Regarding short-term risk, VALN is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for VALN.Check CELC's competition here
Veradermics, Incorporated (NYSE: MANE)
VALN vs MANE Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while MANE trades at $96.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas MANE's P/E ratio is -32.79. In terms of profitability, VALN's ROE is -1.53%, compared to MANE's ROE of -0.29%. Regarding short-term risk, VALN is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for VALN.Check MANE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
VALN vs AMLX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, AMLX has a market cap of 4.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while AMLX trades at $38.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas AMLX's P/E ratio is -25.77. In terms of profitability, VALN's ROE is -1.53%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, VALN is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check AMLX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
VALN vs ELVN Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ELVN has a market cap of 4.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ELVN trades at $61.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ELVN's P/E ratio is -35.82. In terms of profitability, VALN's ROE is -1.53%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, VALN is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ELVN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
VALN vs RLAY Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, RLAY has a market cap of 4.3B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while RLAY trades at $19.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas RLAY's P/E ratio is -12.38. In terms of profitability, VALN's ROE is -1.53%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, VALN is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for VALN.Check RLAY's competition here
Opthea Limited (NASDAQ: OPT)
VALN vs OPT Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas OPT's P/E ratio is -1.52. In terms of profitability, VALN's ROE is -1.53%, compared to OPT's ROE of +1.18%. Regarding short-term risk, VALN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for VALN.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
VALN vs PRTC Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas PRTC's P/E ratio is -3.78. In terms of profitability, VALN's ROE is -1.53%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, VALN is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for VALN.Check PRTC's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
VALN vs ADPT Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while ADPT trades at $25.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas ADPT's P/E ratio is -63.39. In terms of profitability, VALN's ROE is -1.53%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, VALN is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for VALN.Check ADPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
VALN vs MRTX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VALN's ROE is -1.53%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VALN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for VALN.Check MRTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
VALN vs LEGN Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while LEGN trades at $20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas LEGN's P/E ratio is -32.09. In terms of profitability, VALN's ROE is -1.53%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, VALN is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for VALN.Check LEGN's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
VALN vs DNLI Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, DNLI has a market cap of 4B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while DNLI trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas DNLI's P/E ratio is -8.65. In terms of profitability, VALN's ROE is -1.53%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, VALN is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for VALN.Check DNLI's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
VALN vs VKTX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while VKTX trades at $32.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas VKTX's P/E ratio is -7.27. In terms of profitability, VALN's ROE is -1.53%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, VALN is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check VKTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
VALN vs TNGX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while TNGX trades at $23.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas TNGX's P/E ratio is -28.77. In terms of profitability, VALN's ROE is -1.53%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, VALN is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for VALN.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
VALN vs CPRX Comparison August 2026
Valneva SE (NASDAQ: VALN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VALN stands at 660M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, VALN is priced at $6.76 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VALN currently has a P/E ratio of -3.30, whereas CPRX's P/E ratio is 12.30. In terms of profitability, VALN's ROE is -1.53%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VALN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for VALN.Check CPRX's competition here